ATE179983T1 - Antiretrovirale, enantiomere nukleotid-analoge - Google Patents
Antiretrovirale, enantiomere nukleotid-analogeInfo
- Publication number
- ATE179983T1 ATE179983T1 AT93918659T AT93918659T ATE179983T1 AT E179983 T1 ATE179983 T1 AT E179983T1 AT 93918659 T AT93918659 T AT 93918659T AT 93918659 T AT93918659 T AT 93918659T AT E179983 T1 ATE179983 T1 AT E179983T1
- Authority
- AT
- Austria
- Prior art keywords
- antiretroviral
- nucleotide analogues
- enantiomeric nucleotide
- compounds
- enantiomeric
- Prior art date
Links
- 230000000798 anti-retroviral effect Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6521—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/925,610 US6057305A (en) | 1992-08-05 | 1992-08-05 | Antiretroviral enantiomeric nucleotide analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE179983T1 true ATE179983T1 (de) | 1999-05-15 |
Family
ID=25451994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93918659T ATE179983T1 (de) | 1992-08-05 | 1993-08-04 | Antiretrovirale, enantiomere nukleotid-analoge |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6057305A (de) |
| EP (2) | EP0897917A1 (de) |
| JP (2) | JP4083691B2 (de) |
| AT (1) | ATE179983T1 (de) |
| CA (2) | CA2141589C (de) |
| CZ (2) | CZ290797B6 (de) |
| DE (1) | DE69324923T2 (de) |
| DK (1) | DK0654037T3 (de) |
| ES (1) | ES2131116T3 (de) |
| GR (1) | GR3030754T3 (de) |
| SG (1) | SG47761A1 (de) |
| WO (1) | WO1994003467A2 (de) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| KR100386685B1 (ko) * | 1993-09-17 | 2003-12-31 | 길리애드 사이언시즈, 인코포레이티드 | 뉴클레오타이드동족체류 |
| IT1270008B (it) * | 1994-09-23 | 1997-04-16 | Ist Superiore Sanita | Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| KR19990022752A (ko) * | 1995-06-15 | 1999-03-25 | 미우라 아끼라 | 포스포네이트 뉴클레오티드 유도체 |
| US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
| CN101239989B (zh) * | 1996-07-26 | 2012-12-12 | 吉联亚科学股份有限公司 | 核苷酸类似物 |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| EP1243590B1 (de) * | 1997-07-25 | 2005-02-09 | Gilead Sciences, Inc. | Nukleotid-Analog Zusamensetzung und Synthese Verfahren |
| PT1243590E (pt) * | 1997-07-25 | 2005-05-31 | Gilead Sciences Inc | Composicao de analogos nuclotidicos e metodo de sintese |
| WO1999008110A1 (en) | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
| IL137164A0 (en) | 1998-01-23 | 2001-07-24 | Newbiotics Inc | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US6683061B1 (en) * | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| MXPA02000762A (es) | 1999-07-22 | 2002-08-20 | Newbiotics Inc | Metodos para tratar tumores resistentes a terapia. |
| WO2001044257A1 (en) * | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| OA12393A (en) | 2000-07-21 | 2006-04-18 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. |
| CA2441350A1 (en) | 2001-01-19 | 2002-07-25 | Newbiotics, Inc. | Methods to treat autoimmune and inflammatory conditions |
| CZ297267B6 (cs) | 2001-06-29 | 2006-10-11 | Ústav organické chemie a biochemie AV CR | Deriváty pyrimidinu nesoucí fosfonátovou skupinu,zpusob jejich prípravy, jejich pouzití pro lécbu a farmaceutické prípravky tyto látky obsahující |
| JP2005508924A (ja) * | 2001-08-30 | 2005-04-07 | 三菱ウェルファーマ株式会社 | 抗ウイルス剤 |
| EA200400690A1 (ru) * | 2001-11-14 | 2005-06-30 | Байокрист Фармасьютикалз, Инк. | Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз |
| US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| SI1583542T1 (sl) * | 2003-01-14 | 2008-12-31 | Gilead Sciences Inc | Sestavki in postopki za kombinacijsko antivirusnoterapijo |
| EP1644389B1 (de) | 2003-06-16 | 2011-01-19 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga |
| WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| US9512125B2 (en) * | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| EP1831235B1 (de) | 2004-12-16 | 2013-02-20 | The Regents of The University of California | Arzneimittel für die lungen |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| WO2006114064A2 (en) * | 2005-04-25 | 2006-11-02 | Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| US20080317852A1 (en) * | 2005-12-14 | 2008-12-25 | Amar Lulla | Pharmaceutical Combination |
| KR101499783B1 (ko) * | 2006-04-04 | 2015-03-09 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20080318904A1 (en) * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched tenofovir |
| US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| AU2009204483B2 (en) * | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| JP5547099B2 (ja) * | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| WO2010014134A1 (en) * | 2008-07-02 | 2010-02-04 | Idenix Pharamaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| MX2011000216A (es) * | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| CA2800670C (en) | 2010-06-11 | 2020-02-18 | Gilead Sciences, Inc. | Topical antiviral formulations |
| US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112013014485B1 (pt) | 2010-12-10 | 2021-03-30 | Sigmapharm Laboratories, Llc | Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições |
| ZA201103820B (en) | 2010-12-13 | 2012-01-25 | Laurus Labs Private Ltd | Process for the preparation of tenofovir |
| KR20180080358A (ko) | 2011-01-10 | 2018-07-11 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| EP2691409B1 (de) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Verbindungen und zusammensetzungen zur behandlung von virusinfektionen |
| WO2012137227A2 (en) * | 2011-04-08 | 2012-10-11 | Laurus Labs Private Limited | Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof |
| JP5847296B2 (ja) | 2011-05-10 | 2016-01-20 | アラタナ セラピューティクス エン ヴェー | ネコレトロウイルス感染症の治療に使用するための化合物 |
| CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| EP2734530A1 (de) | 2011-07-19 | 2014-05-28 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und ihre verwendung |
| CN103998442B (zh) | 2011-08-29 | 2016-09-14 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| WO2013072745A1 (en) | 2011-11-16 | 2013-05-23 | Laurus Labs Private Limited | Process for the preparation of tenofovir |
| WO2013095684A1 (en) | 2011-12-22 | 2013-06-27 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| WO2014052669A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| IL291945B2 (en) | 2012-11-01 | 2025-11-01 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| CN107056838A (zh) | 2013-03-15 | 2017-08-18 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CN104230934B (zh) * | 2013-06-08 | 2016-12-28 | 上海医药工业研究院 | 一种化合物及其制备方法和用途 |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| CN103641857B (zh) * | 2013-12-20 | 2016-08-24 | 石药集团中诺药业（石家庄）有限公司 | 一种替诺福韦新晶型及其制备方法 |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| EP4066834A1 (de) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| SG11201701957XA (en) | 2014-09-15 | 2017-04-27 | Univ California | Nucleotide analogs |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10202105371YA (en) | 2014-12-26 | 2021-07-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| FI3706762T3 (fi) | 2017-12-07 | 2024-12-13 | Univ Emory | N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN115677774B (zh) * | 2021-07-23 | 2025-04-22 | 上海医药工业研究院有限公司 | 膦酸酯衍生物及其制备方法和用途 |
| KR20250052378A (ko) | 2022-07-21 | 2025-04-18 | 안티바 바이오사이언시즈, 인크. | Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB544419A (en) * | 1940-01-08 | 1942-04-13 | Union Special Machine Co | Improvements in or relating to sewing machines |
| GB1544419A (en) * | 1975-11-19 | 1979-04-19 | Science Union & Cie | Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them |
| US4221910A (en) * | 1978-09-15 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | 9-(Hydroxy alkyl)purines |
| CS233665B1 (en) * | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| DE3490262T1 (de) * | 1983-05-24 | 1985-11-28 | Sri International, Menlo Park, Calif. | Antivirus-Mittel |
| IL72173A0 (en) * | 1983-06-24 | 1984-10-31 | Merck & Co Inc | Guanine derivatives,their preparation and pharmaceutical compositions containing them |
| US4556727A (en) * | 1984-07-18 | 1985-12-03 | University Patents, Inc. | Ferroelectric smectic liquid crystals |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| CS263952B1 (en) * | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| DE3789347D1 (de) * | 1986-10-14 | 1994-04-21 | Banyu Pharma Co Ltd | 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung. |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| NZ222553A (en) * | 1986-11-18 | 1991-07-26 | Bristol Myers Co | Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions |
| DE3883070T2 (de) * | 1987-05-18 | 1994-01-27 | Canon Kk | Polymer-Flüssigkristallzusammensetzung und Flüssigkristallvorrichtung. |
| JP2580205B2 (ja) * | 1987-10-21 | 1997-02-12 | チッソ株式会社 | 光学活性−２−ビフェニリルピリジン類 |
| IE75342B1 (en) * | 1987-12-25 | 1997-08-27 | Daiichi Seiyaku Co | Propoxybenzene derivatives and process for preparing the same |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| AU4376589A (en) * | 1988-11-07 | 1990-05-10 | Gist-Brocades N.V. | Optically active benzoxazines and benzothiazines |
| DE3906357A1 (de) * | 1989-03-01 | 1990-09-06 | Boehringer Mannheim Gmbh | Neue acyclische nucleosid-analoga, verfahren zu ihrer herstellung und verwendung dieser verbindungen als antivirale arzneimittel |
| EP0452935B1 (de) * | 1990-04-20 | 1995-06-21 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Chirale 2-(Phosphonomethoxy)propyl-Guanine als antivirale Agentien |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| CZ285420B6 (cs) * | 1990-04-24 | 1999-08-11 | Ústav Organické Chemie A Biochemie Avčr | N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití |
| CS276072B6 (en) * | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF |
| DE69132276T2 (de) * | 1990-08-10 | 2001-03-01 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha | Verfahren zur herstellung von nukleotiden |
| DE69129650T2 (de) * | 1990-09-14 | 1999-03-25 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha | Wirkstoffvorläufer von Phosphonaten |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| EP0763048A1 (de) * | 1994-05-31 | 1997-03-19 | Medivir Aktiebolag | Hiv-infektionsverhütung nach kontakt mit dem virus |
-
1992
- 1992-08-05 US US07/925,610 patent/US6057305A/en not_active Expired - Lifetime
-
1993
- 1993-08-04 CA CA002141589A patent/CA2141589C/en not_active Expired - Lifetime
- 1993-08-04 CZ CZ1995272A patent/CZ290797B6/cs not_active IP Right Cessation
- 1993-08-04 AT AT93918659T patent/ATE179983T1/de active
- 1993-08-04 SG SG1996004260A patent/SG47761A1/en unknown
- 1993-08-04 ES ES93918659T patent/ES2131116T3/es not_active Expired - Lifetime
- 1993-08-04 CZ CZ2001529A patent/CZ293533B6/cs not_active IP Right Cessation
- 1993-08-04 WO PCT/US1993/007360 patent/WO1994003467A2/en not_active Ceased
- 1993-08-04 EP EP98119443A patent/EP0897917A1/de not_active Withdrawn
- 1993-08-04 DK DK93918659T patent/DK0654037T3/da active
- 1993-08-04 CA CA002574904A patent/CA2574904C/en not_active Expired - Lifetime
- 1993-08-04 US US08/379,551 patent/US6653296B1/en not_active Expired - Lifetime
- 1993-08-04 EP EP93918659A patent/EP0654037B1/de not_active Expired - Lifetime
- 1993-08-04 DE DE69324923T patent/DE69324923T2/de not_active Expired - Lifetime
-
1999
- 1999-07-14 GR GR990401839T patent/GR3030754T3/el unknown
-
2000
- 2000-02-08 US US09/500,148 patent/US6479673B1/en not_active Expired - Fee Related
-
2004
- 2004-02-05 JP JP2004029994A patent/JP4083691B2/ja not_active Expired - Lifetime
-
2007
- 2007-12-18 JP JP2007326607A patent/JP2008120820A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08503927A (ja) | 1996-04-30 |
| CA2574904A1 (en) | 1994-02-17 |
| CA2141589C (en) | 2007-04-17 |
| US6479673B1 (en) | 2002-11-12 |
| JP4083691B2 (ja) | 2008-04-30 |
| JP3561272B2 (ja) | 2004-09-02 |
| CZ290797B6 (cs) | 2002-10-16 |
| CA2574904C (en) | 2009-06-16 |
| GR3030754T3 (en) | 1999-11-30 |
| CZ293533B6 (cs) | 2004-05-12 |
| CZ27295A3 (en) | 1995-12-13 |
| ES2131116T3 (es) | 1999-07-16 |
| EP0654037A1 (de) | 1995-05-24 |
| SG47761A1 (en) | 1998-04-17 |
| WO1994003467A3 (en) | 1994-06-23 |
| US6653296B1 (en) | 2003-11-25 |
| HK1011998A1 (en) | 1999-07-23 |
| WO1994003467A2 (en) | 1994-02-17 |
| DK0654037T3 (da) | 1999-11-01 |
| CA2141589A1 (en) | 1994-02-17 |
| JP2008120820A (ja) | 2008-05-29 |
| EP0897917A1 (de) | 1999-02-24 |
| JP2004189750A (ja) | 2004-07-08 |
| US6057305A (en) | 2000-05-02 |
| EP0654037B1 (de) | 1999-05-12 |
| DE69324923D1 (de) | 1999-06-17 |
| DE69324923T2 (de) | 1999-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE179983T1 (de) | Antiretrovirale, enantiomere nukleotid-analoge | |
| ATE245646T1 (de) | Therapeutische nukleoside | |
| ATE108452T1 (de) | Puringruppen enthaltende cyclobutane. | |
| DE69001187D1 (de) | 6-epifumagillole, ihre herstellung und ihre verwendung. | |
| ATE167679T1 (de) | Wirkstoffvorläufer von phosphonaten | |
| GR3017812T3 (en) | 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof. | |
| SE8500307D0 (sv) | Nya, antiviruella medel | |
| ATE110382T1 (de) | Oxetanocin. | |
| ES2131730T3 (es) | Preparacion de compuestos de guanina n-9 sustituidos. | |
| ES2108016T3 (es) | Triazolopiridazinas substituidas. | |
| DE69231892D1 (de) | Cyclische verbindung | |
| ES2055211T3 (es) | Purinil- y pirimidinil-tetrahidrofuranos. | |
| FR2378518A1 (fr) | Nouveaux medicaments a base de derives de tetrahydrodibenzopyranne | |
| ES2008067T3 (es) | Analogos de prostaciclina (pgi2). | |
| PT1424321E (pt) | Sintese de esteres de ciclo-hexilfenilglicolato opticamente activos | |
| DE68909143D1 (de) | Prostaglandin-Vorläufer und ihre Herstellung. | |
| DK0439058T3 (da) | Acycliske terpener | |
| ATE176242T1 (de) | Uck14-verbindungen | |
| DK0717731T3 (da) | Antivirale difluorstatonanaloge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |